Pulmonary Complications of Immunotherapy
Bade BC, Possick JD. Pulmonary Complications of Immunotherapy. Clinics In Chest Medicine 2020, 41: 295-305. PMID: 32402364, DOI: 10.1016/j.ccm.2020.02.012.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsLung cancerImmune checkpoint inhibitor therapyImmune-related adverse eventsTreatment-limiting complicationsCheckpoint inhibitor therapyFurther prospective investigationMetastatic lung cancerFavorable safety profileTreatment of patientsPulmonary complicationsAdverse eventsClinical vigilanceInhibitor therapySignificant morbiditySafety profileProspective InvestigationCurrent guidelinesMortality riskImmunotherapyComplicationsPatientsCancerPneumonitisMorbidityChemotherapyCardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing
Medeiros BC, Possick J, Fradley M. Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing. Blood Reviews 2018, 32: 289-299. PMID: 29454474, DOI: 10.1016/j.blre.2018.01.004.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic myeloid leukemiaTyrosine kinase inhibitorsComorbid risk factorsMyeloid leukemiaTyrosine kinase inhibitor therapyPatients' disease profilesTreatment-limiting complicationsAdverse event profileKinase inhibitor therapyTKI selectionInhibitor therapyPrompt managementEvent profileTKI agentsCML treatmentPulmonary disordersPulmonary toxicityRisk factorsToxicity profileMyeloproliferative neoplasmsSymptoms of toxicityDisease profileMetabolic toxicityKinase inhibitorsAppropriate agent